From Nanoparticles to Cancer Nanomedicine: Old Problems with New Solutions

Anticancer nanomedicines have been studied over 30 years, but fewer than 10 formulations have been approved for clinical therapy today. Despite abundant options of anticancer drugs, it remains challenging to have agents specifically target cancer cells while reducing collateral toxicity to healthy t...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiang, Chi-Ling, Cheng, Ming-Huei, Lin, Chih-Hsin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308137/
https://www.ncbi.nlm.nih.gov/pubmed/34209111
http://dx.doi.org/10.3390/nano11071727

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8308137/
https://www.ncbi.nlm.nih.gov/pubmed/34209111
http://dx.doi.org/10.3390/nano11071727

Ejemplares similares